Personalized cancer vaccine and adoptive T cell therapy benefits patients with advanced ovarian cancer: Study

by

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

Leave A Comment

Your email address will not be published. Required fields are marked *